🔴 Summit Therapeutics is trading 4.1% down today on lingering trial and earnings concerns

Summit Therapeutics is trading at $14.45 (down 4.1%) as shares continue to drift lower following recent clinical and financial setbacks.

• Investor sentiment remains pressured by lingering concerns from the HARMONi-3 trial miss and a wider-than-expected Q1 2026 loss.
• The stock is facing continued headwinds from prior shelf registration-related dilution worries, despite no new company-specific news being reported today.
• Shares have experienced heightened volatility as the market digests the company's long-term clinical and financial outlook.